MétaCan
Menu
Back to cohort
Record W4386203424 · doi:10.1038/s41591-023-02526-x

Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial

2023· article· en· W4386203424 on OpenAlex

Why this work is in the frame

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

affAt least one author lists a Canadian institution in the pinned OpenAlex snapshot.
fundA Canadian funder is recorded on the work.

Bibliographic record

VenueNature Medicine · 2023
Typearticle
Languageen
FieldMedicine
TopicCardiovascular Function and Risk Factors
Canadian institutionsUniversity of TorontoUniversity of AlbertaSt. Michael's Hospital
FundersNational Center for Advancing Translational SciencesNational Heart, Lung, and Blood InstituteNational Institute on AgingMedizinische Fakultät der Albert-Ludwigs-Universität FreiburgCanadian Institutes of Health ResearchAmerican RegentFeinberg School of MedicineNational Institutes of HealthINCLIVA Instituto de Investigación SanitariaSahlgrenska UniversitetssjukhusetUniwersytet ŁódzkiDaiichi-SankyoAlbert-Ludwigs-Universität FreiburgKarl-Franzens-Universität GrazGentofte HospitalDeutsche ForschungsgemeinschaftSun PharmaAustralian National UniversityUniversity of AlbertaUniversity of TorontoUniversity of GlasgowBritish Heart FoundationNational Institute for Health and Care ResearchImpulse DynamicsNGM BiopharmaceuticalsAlnylam PharmaceuticalsAstraZenecaSaint Luke's Health SystemCytokineticsProthenaAmarin CorporationRegeneron PharmaceuticalsBoston Scientific CorporationPfizerNorthwestern UniversityUniversity of MissouriHLS TherapeuticsUniversitair Medisch Centrum GroningenUnited Therapeutics CorporationEli Lilly and CompanyU.S. Department of DefenseSanofiUniversity of Missouri-Kansas CityMedizinische Universität GrazGedeon RichterLivaNovaGlaxoSmithKlineKawasaki Medical SchoolHeart and Stroke Foundation of CanadaRijksuniversiteit GroningenBristol-Myers SquibbEdwards LifesciencesAmgenNovo NordiskMyoKardiaServierGilead Sciences
KeywordsMedicineSemaglutideInternal medicineObesityHeart failure with preserved ejection fractionCardiologyWeight lossBlood pressureDiabetes mellitusDiastoleEndocrinologyType 2 diabetes

Abstract

fetched live from OpenAlex

Abstract In the STEP-HFpEF trial, semaglutide improved symptoms, physical limitations and exercise function and reduced body weight in patients with obesity phenotype of heart failure and preserved ejection fraction (HFpEF). This prespecified analysis examined the effects of semaglutide on dual primary endpoints (change in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) and body weight) and confirmatory secondary endpoints (change in 6-minute walk distance (6MWD), hierarchical composite (death, HF events, change in KCCQ-CSS and 6MWD) and change in C-reactive protein (CRP)) across obesity classes I–III (body mass index (BMI) 30.0–34.9 kg m − 2 , 35.0–39.9 kg m − 2 and ≥40 kg m − 2 ) and according to body weight reduction with semaglutide after 52 weeks. Semaglutide consistently improved all outcomes across obesity categories ( P value for treatment effects × BMI interactions = not significant for all). In semaglutide-treated patients, improvements in KCCQ-CSS, 6MWD and CRP were greater with larger body weight reduction (for example, 6.4-point (95% confidence interval (CI): 4.1, 8.8) and 14.4-m (95% CI: 5.5, 23.3) improvements in KCCQ-CSS and 6MWD for each 10% body weight reduction). In participants with obesity phenotype of HFpEF, semaglutide improved symptoms, physical limitations and exercise function and reduced inflammation and body weight across obesity categories. In semaglutide-treated patients, the magnitude of benefit was directly related to the extent of weight loss. Collectively, these data support semaglutide-mediated weight loss as a key treatment strategy in patients with obesity phenotype of HFpEF. ClinicalTrials.gov identifier: NCT04788511 .

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.401
Threshold uncertainty score0.461

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.004
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.011
GPT teacher head0.298
Teacher spread0.287 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it